Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
13.66
-0.16 (-1.16%)
At close: May 21, 2025, 4:00 PM
13.66
0.00 (0.00%)
After-hours: May 21, 2025, 5:53 PM EDT
Viridian Therapeutics Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Viridian Therapeutics stock ranges from a low of $27 to a high of $61. The average analyst price target of $38.5 forecasts a 181.84% increase in the stock price over the next year.
Price Target: $38.50 (+181.84%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 6 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +163.54% | May 20, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $46 → $45 | Buy | Maintains | $46 → $45 | +229.43% | May 7, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $31 → $27 | Strong Buy | Maintains | $31 → $27 | +97.66% | May 7, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $42 → $38 | Buy | Maintains | $42 → $38 | +178.18% | May 7, 2025 |
| Needham | Needham | Strong Buy Maintains $38 → $36 | Strong Buy | Maintains | $38 → $36 | +163.54% | May 7, 2025 |
Financial Forecast
Revenue This Year
186.20K
from 302.00K
Decreased by -38.34%
Revenue Next Year
41.11M
from 186.20K
Increased by 21,976.14%
EPS This Year
-4.04
from -3.07
EPS Next Year
-3.96
from -4.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 863,100 | 96.9M | 428.4M | ||
| Avg | 186,201 | 41.1M | 268.2M | ||
| Low | n/a | n/a | 102.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 185.8% | 51,948.6% | 942.2% | ||
| Avg | -38.3% | 21,976.1% | 552.5% | ||
| Low | - | - | 150.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.42 | -2.99 | -1.25 | ||
| Avg | -4.04 | -3.96 | -2.18 | ||
| Low | -5.28 | -4.53 | -2.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.